OSE Immunotherapeutics (XPAR:OSE) Debt-to-Equity : 1.99 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is OSE Immunotherapeutics Debt-to-Equity?

OSE Immunotherapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €7.26 Mil. OSE Immunotherapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €38.54 Mil. OSE Immunotherapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €22.98 Mil. OSE Immunotherapeutics's debt to equity for the quarter that ended in Dec. 2023 was 1.99.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for OSE Immunotherapeutics's Debt-to-Equity or its related term are showing as below:

XPAR:OSE' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.47 Med: 0.14 Max: 1.99
Current: 1.99

During the past 12 years, the highest Debt-to-Equity Ratio of OSE Immunotherapeutics was 1.99. The lowest was -1.47. And the median was 0.14.

XPAR:OSE's Debt-to-Equity is ranked worse than
94.93% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs XPAR:OSE: 1.99

OSE Immunotherapeutics Debt-to-Equity Historical Data

The historical data trend for OSE Immunotherapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OSE Immunotherapeutics Debt-to-Equity Chart

OSE Immunotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.20

0.32

0.78

1.37

1.99

OSE Immunotherapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.78	0.76	1.37	1.94	1.99

Competitive Comparison of OSE Immunotherapeutics's Debt-to-Equity

For the Biotechnology subindustry, OSE Immunotherapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OSE Immunotherapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OSE Immunotherapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where OSE Immunotherapeutics's Debt-to-Equity falls into.

OSE Immunotherapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

OSE Immunotherapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.261	+	38.541)	/	22.975
	=	1.99

OSE Immunotherapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.261	+	38.541)	/	22.975
	=	1.99

OSE Immunotherapeutics (XPAR:OSE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

OSE Immunotherapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of OSE Immunotherapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

OSE Immunotherapeutics (XPAR:OSE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OSE Immunotherapeutics SA (XPAR:OSE) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

6OP:Germany

Address

22, Boulevard Benoni Goullin, Nantes, FRA, 44200

Website

http://www.ose-immuno.com

OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.

OSE Immunotherapeutics (XPAR:OSE) Headlines

No Headlines